Press release

The Forever Healthy Foundation today publicly launched evipedia.ai, an open online encyclopedia of in-depth evidence reviews covering more than 500 health and longevity interventions, including first-generation rejuvenation therapies, supplements, botanicals, lifestyle protocols, and more. Evipedia was built to solve a problem familiar to anyone navigating the longevity field: the literature is vast, fragmented, fast-moving, and...

Beijing, China — In response to the growing healthcare demands of a rapidly ageing population, China has launched its first national competency-based education programme in longevity medicine, marking a significant step toward integrating healthy longevity and preventive care into mainstream clinical practice. The initiative was jointly developed by the China Non-public Medical Institutions Association and...

Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and remove toxic targets to address root causes of age-related disease, has just unveiled data from a clinical trial of its lead candidate, UDP-003, at the American Heart Association Vascular Discovery Scientific Sessions. Data from a study...

We are super excited to share with you that today we released AI4L - "AI for Practical Longevity", an open-source system that enables anyone to produce rigorous, evidence-based reviews of health and longevity interventions using frontier AI models. Our novel "Audit-Driven Prompting" method enables iterative self-auditing and eliminates hallucinations with live citation verification and zero-tolerance...

Longevity Day at NFC Summit Lisbon has announced its confirmed speaker lineup ahead of its debut on 4 June 2026 at the Unicorn Factory in Lisbon. The event will bring together scientists, clinicians, founders, and investors from across the longevity ecosystem for a full-day program spanning ancestral wisdom, cutting-edge science, and frontier biotech. The event...

BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today reported results from the Phase 1 clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor. The full dataset, which includes a...